|
|
|
|
Monday, August 12, 2019
Trovagene Inc. (TROV)
Additional Data Readouts are the Major Inflection Points in H2 2019
TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Opportunity in Multiple Indications. Trovagene continues to make progress in its clinical programs including; 1) Phase 1b/2 study in acute myeloid leukemia (AML), 2) Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) and 3) Phase 1b/2 trial in KRAS-mutated metastatic colorectal cancer (mCRC).
- Key Value Driving Catalysts. In our view, additional data readouts, validating the potential of Onvansertib in these indications, will unlock additional value for the shares. The nearest-term catalyst is…
Get full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
